Recent Update of HDAC Inhibitors in Lymphoma
Modulating epigenetic modification has been recognized for over a decade as an effective therapeutic approach to cancer and many studies of histone deacetylase (HDAC), one of the best known epigenetic modulators, have been published. HDAC modulates cell proliferation and angiogenesis and plays an es...
Main Authors: | I-Chung Chen, Bidyadhar Sethy, Jing-Ping Liou |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-09-01
|
Series: | Frontiers in Cell and Developmental Biology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fcell.2020.576391/full |
Similar Items
-
HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma
by: Xiaoguang Wang, et al.
Published: (2020-03-01) -
Updates in the Treatment of Peripheral T-Cell Lymphomas
by: Saleh K, et al.
Published: (2021-06-01) -
HDAC Inhibitors: Therapeutic Potential in Fibrosis-Associated Human Diseases
by: Somy Yoon, et al.
Published: (2019-03-01) -
HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity
by: Dimitris Karagiannis, et al.
Published: (2021-07-01) -
The efficacy of HDAC inhibitors in neoplasm treatment
by: Dominika Psiuk, et al.
Published: (2020-08-01)